DiaMedica Therapeutics Establishes $100 Million At-The-Market Equity Offering Program

DiaMedica Therapeutics, Inc. (NASDAQ: DMAC), a clinical stage biopharmaceutical company committed to improving the lives of people suffering from preeclampsia and acute ischemic stroke, established an at-the-market equity offering program (ATM Program) with representation from Faegre Drinker. Pursuant to the ATM Program, DiaMedica may offer and sell shares of its common stock with an aggregate gross sales price of up to $100 million. TD Securities (USA) LLC (TD Cowen) is serving as the sales agent for the ATM Program.